(Q38036769)

27 August 2017

The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety (English)

1 reference

27 August 2017

1 reference

Jennifer B Green

1

1 reference

PubMed ID

22913894

27 August 2017

language of work or name

English

0 references

publication date

1 July 2012

1 reference

27 August 2017

Postgraduate Medicine

1 reference

27 August 2017

124

1 reference

27 August 2017

4

1 reference

27 August 2017

54-61

1 reference

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

27 August 2017

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2566

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2566

Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2566

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2566

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2566

Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2566

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2566

Clinical endocrinology and metabolism. Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2566

Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2566

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2566

Cardiovascular biology of the incretin system

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2566

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2566

DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2566

Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2566

Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2566

The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2566

DPP-4 inhibitors in clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2566

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2566

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2566

Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2566

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2566

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2566

The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2566

DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2566

Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2566

Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2566

21 January 2018

Identifiers

DOI

10.3810/PGM.2012.07.2566

1 reference

27 August 2017

1 reference

PubMed ID

22913894